RCOphth invited to address issues of capacity at a meeting of the All Party Parliamentary Group for Eye Health and Visual Impairment.
Miss Corbett commented, ‘The demand on eye services has increased by 30% over the last five years in the UK. This is largely due to an ageing population with the associated chronic diseases such as glaucoma, age related macular degeneration (AMD) and diabetes.’
Professor Carrie MacEwen and Professor Andrew Lotery co-author the editorial ‘What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?’, published online on BMJ, calls for UK regulatory bodies to review and appraise use of bevacizumab for use in AMD treatment.
Chief Medical Officer’s Letter regarding patients on planned waiting lists
In November 2011 the CMO and the Deputy NHS Chief Executive wrote to Trusts stating it is unacceptable for patients to be waiting inappropriately which has impacted on clinical outcomes.